Prospective Grant of Exclusive License: Electron Paramagnetic Resonance Devices and Systems for Oximetry, 67200-67201 [2011-28131]

Download as PDF 67200 Federal Register / Vol. 76, No. 210 / Monday, October 31, 2011 / Notices DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Proposed National Toxicology Program (NTP) Review Process for the Report on Carcinogens: Request for Public Comment and Listening Session Division of the National Toxicology Program (DNTP), National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH). AGENCY: Request for public comment and announcement of listening session. ACTION: The NTP invites written public comment on the proposed Report on Carcinogens (RoC) review process and announces a public listening session to receive oral comments on the proposed process. SUMMARY: The deadline for submission of written comments is November 30, 2011, and the deadline to register for the public listening session is November 21, 2011. The public listening session will be held November 29, 2011, 1–5 p.m. (EST), although it may end earlier depending on the number of registered speakers and will be cancelled if there are no registrants by the close of business (COB) on November 21, 2011. Registrants will receive information to access the listening session on or before November 22, 2011, and speakers should send talking points or slides by COB on November 21, 2011. DATES: Written comments should be sent to Dr. Ruth Lunn, Director, Office of the Report on Carcinogens, DNTP, NIEHS, P.O. Box 12233, MD K2– 14, Research Triangle Park, NC 27709; telephone: (919) 316–4637 or email lunn@niehs.nih.gov. Courier address: NIEHS, Room 2006, 530 Davis Drive, Morrisville, NC 27560. Registration for the listening session is via the NTP Web site (https://ntp.niehs.nih.gov/go/ rocprocess). TTY users should contact the Federal TTY Relay Service at (800) 877–8330. Requests must be made at least 5 business days in advance of the listening session. ADDRESSES: jlentini on DSK4TPTVN1PROD with NOTICES FOR FURTHER INFORMATION CONTACT: Questions or comments should be directed to Dr. Lunn (see ADDRESSES). SUPPLEMENTARY INFORMATION: VerDate Mar<15>2010 17:21 Oct 28, 2011 Jkt 226001 Background Information on the RoC and its Review Process The RoC is a science-based, public health document, required by Congress to be published every two years (Public Health Services Act sec. 301(b)(4), 42 U.S.C. 241(b)(4)). The RoC provides information on substances that may pose a hazard to human health by virtue of their carcinogenicity (for more information see https:// ntp.niehs.nih.gov/go/roc). Substances are listed in the report as either known or reasonably anticipated human carcinogens. The NTP prepares the RoC on behalf of the Secretary of Health and Human Services. The 12th RoC was published in June 2011. The NTP followed an established process for the review of substances for the 12th RoC. The NTP is proposing changes to the review process for listing substances in the 13th RoC to enhance transparency and efficiency and to enable the NTP to publish the RoC in a timelier manner. The NTP also seeks to maintain critical elements of the existing process including external scientific and public involvement, scientific rigor, and external peer review. The proposed RoC review process is available on the NTP RoC Web site (https://ntp.niehs.nih.gov/go/ rocprocess). or observers must register by November 21, 2011, at https://ntp.niehs.nih.gov/go/ rocprocess. There will be 50 connections available for registrants including speakers plus observers. Registration to present oral remarks is limited to the first 15 registrants who wish to speak with one time slot per organization. The NTP will send registrants instructions to access the listening session on or before November 22, 2011. A maximum of 15 minutes will be allotted per speaker. Registered speakers should submit their oral statement and/or slides to Dr. Lunn by COB on November 21, 2011. All statements and/or slides will be posted on the RoC Web site with the speaker identified by name, affiliation, and/or sponsoring organization. The NTP will carefully review both the written and oral comments received on the proposed RoC review process and consider what changes, if any, might be needed. The NTP plans to post the finalized RoC review process on the RoC Web site (https://ntp.niehs.nih.gov/ go/rocprocess) and present it at the next NTP Board of Scientific Counselors meeting on December 15, 2011. Details about this meeting will be published in the Federal Register and posted on the NTP Web site at https:// ntp.niehs.nih.gov/go/165. Request for Public Comment The NTP invites written and oral comments on the proposed RoC review process. Written comments should be sent to Dr. Ruth Lunn (see ADDRESSES) by November 30, 2011. Individuals submitting written public comments are asked to include relevant contact information (name, affiliation and sponsoring organization (if any), telephone, and email). Written submissions will be posted on the RoC Web site as they are received and the submitter will be identified by name, affiliation, and/or sponsoring organization. The NTP will hold a listening session using Adobe® ConnectTM on November 29, 2011, from 1–5 p.m. (EST) to receive oral comments on the proposed RoC review process. The listening session may end earlier depending on the number of registered speakers and will be cancelled if there are no registrants by COB on November 21, 2011. If the event is cancelled, notification will be posted on the RoC Web site (https:// ntp.niehs.nih.gov/go/rocprocess). Individuals who wish to participate in the listening session as either speakers Dated: October 24, 2011. John R. Bucher, Associate Director, National Toxicology Program. PO 00000 Frm 00073 Fmt 4703 Sfmt 4703 [FR Doc. 2011–28132 Filed 10–28–11; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Prospective Grant of Exclusive License: Electron Paramagnetic Resonance Devices and Systems for Oximetry National Institutes of Health, Public Health Service, HHS. ACTION: Notice. AGENCY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), Department of Health and Human Services (HHS), is contemplating the grant of an exclusive worldwide license to practice the invention embodied in: HHS Ref. No. E–175–1995/0 and/1; SUMMARY: E:\FR\FM\31OCN1.SGM 31OCN1 Federal Register / Vol. 76, No. 210 / Monday, October 31, 2011 / Notices 67201 Patent/Application No. Territory Filing date Status 5,678,548 ....................................................................................... 5,828,216 ....................................................................................... 5,865,146 ....................................................................................... PCT/US1996/11879 ....................................................................... US ............................................. US ............................................. US ............................................. WIPO ......................................... July 20, 1995 ............................ August 19, 1996 ........................ July 29, 1997 ............................ July 18, 1996 ............................ Issued. Issued. Issued. Expired. Patent/Application No. Territory Filing date Status 61/200,579 ..................................................................................... PCT/US2009/65956 ....................................................................... 13/131,165 ..................................................................................... 09829806.0 .................................................................................... US ............................................. WIPO ......................................... US ............................................. EP ............................................. jlentini on DSK4TPTVN1PROD with NOTICES and HHS Ref. No. E–250–2008/0; to Resonance Research, Inc., a company incorporated under the laws of the Commonwealth of Massachusetts having its headquarters in Billerica, Massachusetts. The United States of America is the assignee of the rights of the above inventions. The contemplated exclusive license may be granted in a field of use limited to electron paramagnetic resonance devices and systems for oximetry. DATES: Only written comments and/or applications for a license received by the NIH Office of Technology Transfer on or before November 15, 2011 will be considered. ADDRESSES: Requests for a copy of the patent application, inquiries, comments and other materials relating to the contemplated license should be directed to: Michael A. Shmilovich, Esq., Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852–3804; Telephone: (301) 435– 5019; Facsimile: (301) 402–0220; Email: shmilovm@mail.nih.gov. A signed confidentiality nondisclosure agreement will be required to receive copies of any patent applications that have not been published by the United States Patent and Trademark Office or the World Intellectual Property Organization. SUPPLEMENTARY INFORMATION: The patents and patent applications intended for licensure disclose or cover devices and systems for in vivo quantitative oximetry using low frequency time-domain EPR imaging in the frequency range of 250–300 MHz. The systems developed use a timedomain spectroscopic EPR imaging approach that is a unique combination of: (1) multi-gradient Single Point Imaging involving global phase encoding and (2) conventional 90°-t180° Spin-Echo pulse sequence wellknown in MRI where the images are obtained by the filtered back-projection after FT of the echoes collected under VerDate Mar<15>2010 17:21 Oct 28, 2011 Jkt 226001 frequency-encoding gradients. The combination approach of single point imaging with the spin-echo signal detection procedure to take advantage of T2 (and not T2*) dependent contrast and the enhanced spatial resolution associated with the constant-time pure phase-encoding approach. This approach has become feasible because of the availability of non-toxic watersoluble trityl and deuterated trityl based spin probes which have reasonable T1 and T2 in the range 5–10 ms. The prospective exclusive license will be royalty bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within fifteen (15) days from the date of this published notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7. Properly filed competing applications for a license filed in response to this notice will be treated as objections to the contemplated license. Comments and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552. Dated: October 25, 2011. Richard U. Rodriguez, Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health. [FR Doc. 2011–28131 Filed 10–28–11; 8:45 am] BILLING CODE 4140–01–P PO 00000 Frm 00074 Fmt 4703 Sfmt 4703 November 29, November 25, May 25, 2011 November 25, 2008 .................. 2009 .................. ............................ 2009 .................. Expired. Expired. Pending. Pending. DEPARTMENT OF THE INTERIOR Bureau of Safety and Environmental Enforcement (BSEE) [Docket ID No. BOEM–2011–0068; OMB Number 1014–0003] Information Collection Activities: Oil and Gas Production Safety Systems; Submitted for Office of Management and Budget (OMB) Review; Comment Request ACTION: 30-day Notice. To comply with the Paperwork Reduction Act of 1995 (PRA), we are notifying the public that we have submitted to OMB an information collection request (ICR) to renew approval of the paperwork requirements in the regulations under Subpart H, ‘‘Oil and Gas Production Safety Systems.’’ This notice also provides the public a second opportunity to comment on the revised paperwork burden of these regulatory requirements. DATES: You must submit comments by November 30, 2011. ADDRESSES: Submit comments by either fax (202) 395–5806 or email (OIRA_DOCKET@omb.eop.gov) directly to the Office of Information and Regulatory Affairs, OMB, Attention: Desk Officer for the Department of the Interior (1014–0003). Please provide a copy of your comments to BSEE by any of the means below. • Electronically: Go to https:// www.regulations.gov. In the entry titled, ‘‘Enter Keyword or ID,’’ enter BOEM– 2011–0068 then click search. Follow the instructions to submit public comments and view all related materials. We will post all comments. • Email cheryl.blundon@bsee.gov. Mail or hand-carry comments to: Department of the Interior; Bureau of Safety and Environmental Enforcement; Regulations Development Branch; SUMMARY: E:\FR\FM\31OCN1.SGM 31OCN1

Agencies

[Federal Register Volume 76, Number 210 (Monday, October 31, 2011)]
[Notices]
[Pages 67200-67201]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-28131]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Exclusive License: Electron Paramagnetic 
Resonance Devices and Systems for Oximetry

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 
CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), 
Department of Health and Human Services (HHS), is contemplating the 
grant of an exclusive worldwide license to practice the invention 
embodied in: HHS Ref. No. E-175-1995/0 and/1;

[[Page 67201]]



----------------------------------------------------------------------------------------------------------------
        Patent/Application No.                  Territory                 Filing date               Status
----------------------------------------------------------------------------------------------------------------
5,678,548.............................  US.......................  July 20, 1995...........  Issued.
5,828,216.............................  US.......................  August 19, 1996.........  Issued.
5,865,146.............................  US.......................  July 29, 1997...........  Issued.
PCT/US1996/11879......................  WIPO.....................  July 18, 1996...........  Expired.
----------------------------------------------------------------------------------------------------------------

and HHS Ref. No. E-250-2008/0;

----------------------------------------------------------------------------------------------------------------
        Patent/Application No.                  Territory                 Filing date               Status
----------------------------------------------------------------------------------------------------------------
61/200,579............................  US.......................  November 29, 2008.......  Expired.
PCT/US2009/65956......................  WIPO.....................  November 25, 2009.......  Expired.
13/131,165............................  US.......................  May 25, 2011............  Pending.
09829806.0............................  EP.......................  November 25, 2009.......  Pending.
----------------------------------------------------------------------------------------------------------------

to Resonance Research, Inc., a company incorporated under the laws of 
the Commonwealth of Massachusetts having its headquarters in Billerica, 
Massachusetts. The United States of America is the assignee of the 
rights of the above inventions. The contemplated exclusive license may 
be granted in a field of use limited to electron paramagnetic resonance 
devices and systems for oximetry.

DATES: Only written comments and/or applications for a license received 
by the NIH Office of Technology Transfer on or before November 15, 2011 
will be considered.

ADDRESSES: Requests for a copy of the patent application, inquiries, 
comments and other materials relating to the contemplated license 
should be directed to: Michael A. Shmilovich, Esq., Office of 
Technology Transfer, National Institutes of Health, 6011 Executive 
Boulevard, Suite 325, Rockville, MD 20852-3804; Telephone: (301) 435-
5019; Facsimile: (301) 402-0220; Email: shmilovm@mail.nih.gov. A signed 
confidentiality nondisclosure agreement will be required to receive 
copies of any patent applications that have not been published by the 
United States Patent and Trademark Office or the World Intellectual 
Property Organization.

SUPPLEMENTARY INFORMATION: The patents and patent applications intended 
for licensure disclose or cover devices and systems for in vivo 
quantitative oximetry using low frequency time-domain EPR imaging in 
the frequency range of 250-300 MHz. The systems developed use a time-
domain spectroscopic EPR imaging approach that is a unique combination 
of: (1) multi-gradient Single Point Imaging involving global phase 
encoding and (2) conventional 90[deg]-[tau]-180[deg] Spin-Echo pulse 
sequence well-known in MRI where the images are obtained by the 
filtered back-projection after FT of the echoes collected under 
frequency-encoding gradients. The combination approach of single point 
imaging with the spin-echo signal detection procedure to take advantage 
of T2 (and not T2*) dependent contrast and the 
enhanced spatial resolution associated with the constant-time pure 
phase-encoding approach. This approach has become feasible because of 
the availability of non-toxic water-soluble trityl and deuterated 
trityl based spin probes which have reasonable T1 and 
T2 in the range 5-10 [mu]s.
    The prospective exclusive license will be royalty bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. 
The prospective exclusive license may be granted unless, within fifteen 
(15) days from the date of this published notice, NIH receives written 
evidence and argument that establishes that the grant of the license 
would not be consistent with the requirements of 35 U.S.C. 209 and 37 
CFR 404.7.
    Properly filed competing applications for a license filed in 
response to this notice will be treated as objections to the 
contemplated license. Comments and objections submitted in response to 
this notice will not be made available for public inspection, and, to 
the extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552.

    Dated: October 25, 2011.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
[FR Doc. 2011-28131 Filed 10-28-11; 8:45 am]
BILLING CODE 4140-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.